Serum Myostatin Levels and Its Relation to Sarcopenia in Hemodialysis Patients | ||||
| Al-Azhar International Medical Journal | ||||
| Volume 2024, Issue 12, December 2024 | ||||
| DOI: 10.58675/2682-339X.2746 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Ahmed Saad1; Ibrahim Mohamed1; Nader Hussein2; Kareem Hendy1 | ||||
| 1Internal Medicine and Nephrology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt | ||||
| 2Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||
| Abstract | ||||
| Background: Skeletal muscle loss and mass loss that occurs naturally with aging is called sarcopenia. Studies show that skeletal muscle mass and strength begin to decline linearly in the 40s and can lose as much as half their mass by the 80s. Objective: To learn more about how hemodialysis patients' blood myostatin levels relate to sarcopenia. Patients and methods: This cross-sectional study involved 90 participants split into three groups of 30 each and was carried out at the Al-Ahrar Teaching Hospital in Zagazig, Egypt, between March 2023 and June 2024. One group consisted of patients on hemodialysis, another of patients with chronic kidney disease (CKD) in the pre-dialysis phase, and a control group of healthy-looking adults made up group III. Results: The serum myostatin level was negatively connected to the glomerular filtration rate (eGFR) and statistically significant in sarcopenic individuals. Conclusion: Sarcopenia is a frequent side effect of long-term kidney illnesses, and when kidney function declined and dialysis became necessary, the prevalence of sarcopenia rose as well. In CKD patients, myostatin may be utilized as a non-invasive biomarker to diagnose sarcopenia. | ||||
|
Statistics Article View: 10 |
||||
